A Phase II, Double-Masked, Randomized, Controlled Study of KPI-121 0.25% Ophthalmic Suspension Compared to Vehicle in Subjects With Dry Eye Disease

Trial Profile

A Phase II, Double-Masked, Randomized, Controlled Study of KPI-121 0.25% Ophthalmic Suspension Compared to Vehicle in Subjects With Dry Eye Disease

Completed
Phase of Trial: Phase II

Latest Information Update: 21 Jul 2016

At a glance

  • Drugs Loteprednol etabonate (Primary)
  • Indications Dry eyes
  • Focus Therapeutic Use
  • Acronyms Kauai
  • Sponsors Kala Pharmaceuticals
  • Most Recent Events

    • 01 Apr 2015 Primary endpoint 'Ocular Discomfort' has not been met, according to a Kala Pharmaceuticals media release.
    • 01 Apr 2015 Results published in a Kala Pharmaceuticals media release.
    • 01 Apr 2015 Primary endpoint 'Bulbar Conjunctival Hyperemia' has been met, according to a Kala Pharmaceuticals media release.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top